{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:40:08Z","timestamp":1752237608914,"version":"3.41.2"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Recently, a cost-saving, dose-reducing strategy for cefiderocol against gram-negative bacteria with low cefiderocol minimum inhibitory concentrations (MICs) was proposed as an alternative to the standard dosing (ie, 2 g every 8 hours, 3-hours infusion). The objectives of this article are to summarize the available evidence on the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of cefiderocol to support the rationale of the approved dosing and to assess any risk of underexposure with reduced doses (ie, 1 g every 8 hours or 12 hours) regarding higher cefiderocol MICs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Published data from phase 1\u20133 clinical, preclinical effectiveness, and surveillance studies were reviewed, and new population PK simulations were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Most carbapenem-resistant gram-negative isolates displayed cefiderocol MICs up to 4 mg\/L. Single or multiple doses of cefiderocol, up to 4 g, were tested in phase 1 clinical studies, which confirmed a linear PK profile, low metabolism, renal clearance, and penetration into the lungs and soft tissues. Phase 2\u20133 randomized controlled clinical studies have demonstrated the efficacy and safety of cefiderocol at 2 g every 8 hours or renally adjusted doses versus comparators in patients with complicated urinary tract infections, nosocomial pneumonia, and bloodstream infection\/sepsis caused by various carbapenem-susceptible or -resistant gram-negative pathogens. Population PK models incorporating clinical data predicted that the approved dosing regimen of cefiderocol, in contrast to reduced doses, would achieve high probability of target attainment against gram-negative isolates, with cefiderocol MICs of 2\u20134 mg\/L across various infection types and patient populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Administering low-dose cefiderocol to reduce treatment-related costs will lead to treatment failure and prolonged hospitalization and incur further expenses. Therefore, the approved cefiderocol dosing regimen is strongly recommended.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001331","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T14:02:42Z","timestamp":1746194562000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Underexposure and Lack of Efficacy of Cefiderocol by Reduced Dosing in Japanese Patients With Gram-Negative Bacterial Infections"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6269-7884","authenticated-orcid":false,"given":"Naoya","family":"Itoh","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan;"},{"name":"Department of Clinical Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan; and"},{"name":"Department of Infectious Diseases, Nagoya City University East Medical Center, Nagoya, Aichi, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"R2-20250711","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jgar.2024.03.020","article-title":"Global trends in carbapenem- and difficult-to-treat resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018\u20132022","volume":"37","author":"Wise","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"R3-20250711","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1021\/acsinfecdis.4c00218","article-title":"A review of antibacterial candidates with new modes of action","volume":"10","author":"Butler","year":"2024","journal-title":"ACS Infect Dis"},{"key":"R4-20250711","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","article-title":"Antibiotics in the clinical pipeline as of December 2022","volume":"76","author":"Butler","year":"2023","journal-title":"J Antibiot"},{"key":"R6-20250711","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","article-title":"In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance","volume":"38","author":"Kayama","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"R7-20250711","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/antibiotics12050870","article-title":"Beta-lactam dose optimisation in the intensive care unit: targets, therapeutic drug monitoring, and toxicity","volume":"12","author":"Legg","year":"2023","journal-title":"Antibiotics"},{"key":"R8-20250711","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multidrug-resistant bacteria: structure activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur J Med Chem"},{"key":"R12-20250711","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/FTD.0000000000001240","article-title":"Optimizing cefiderocol dosing through population pharmacokinetic\/pharmacodynamic simulation: an assessment of drug cost reductions","volume":"47","author":"Oda","year":"2025","journal-title":"Ther Drug Monit"},{"key":"R13-20250711","doi-asserted-by":"crossref","first-page":"e1437-20","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250711","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcph.1986","article-title":"Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects","volume":"62","author":"Kawaguchi","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"R15-20250711","doi-asserted-by":"crossref","first-page":"e0147424","DOI":"10.1128\/spectrum.01474-24","article-title":"In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including \u03b2-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals","volume":"12","author":"Kimbrough","year":"2024","journal-title":"Microbiol Spectr"},{"key":"R16-20250711","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014\u20132019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb Drug Resist"},{"key":"R19-20250711","doi-asserted-by":"crossref","first-page":"e2031-18","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20250711","doi-asserted-by":"crossref","first-page":"e02163-17","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250711","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R21-20250711","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1093\/jac\/dkae359","article-title":"Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers","volume":"79","author":"Sanz-Codina","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R23-20250711","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R22-20250711","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jbcr\/irae026","article-title":"Bone and skin\/subcutaneous tissue concentrations of cefiderocol during treatment of extensively drug-resistant Pseudomonas aeruginosa","volume":"45","author":"Mueller","year":"2024","journal-title":"J Burn Care Res"},{"key":"R24-20250711","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R25-20250711","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R26-20250711","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R18-20250711","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R27-20250711","doi-asserted-by":"crossref","first-page":"e0237123","DOI":"10.1128\/spectrum.02371-23","article-title":"Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post-hoc analysis","volume":"11","author":"Longshaw","year":"2023","journal-title":"Microbiol Spectr"},{"key":"R28-20250711","doi-asserted-by":"crossref","first-page":"e0034623","DOI":"10.1128\/aac.00346-23","article-title":"In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates","volume":"67","author":"Takemura","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 7","key":"R29-20250711","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R30-20250711","doi-asserted-by":"crossref","first-page":"107150","DOI":"10.1016\/j.ijantimicag.2024.107150","article-title":"GEMARA\/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new \u03b2-lactams and \u03b2-lactamase inhibitors (PROTECT). Activity of cefiderocol and innovative \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double \u03b2-lactamases under high and low permeability conditions","volume":"63","author":"Blanco-Mart\u00edn","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"R31-20250711","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R32-20250711","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d'Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"R33-20250711","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s13054-024-05126-4","article-title":"Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support","volume":"28","author":"Mar\u00edn-Cerezuela","year":"2024","journal-title":"Crit Care"},{"key":"R34-20250711","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40262-021-01086-y","article-title":"Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy","volume":"61","author":"Wenzler","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R35-20250711","doi-asserted-by":"crossref","first-page":"ofae451","DOI":"10.1093\/ofid\/ofae451","article-title":"Validation of cefiderocol package insert dosing recommendation for patients receiving continuous renal replacement therapy: a prospective multicenter pharmacokinetic study","volume":"11","author":"Fouad","year":"2024","journal-title":"Open Forum Infect Dis"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:00:50Z","timestamp":1752235250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001331","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"2024-11-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}